Compare Lupin Ltd with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN vs ASTRAZENECA PHARMA - Comparison Results

LUPIN     Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN ASTRAZENECA PHARMA LUPIN/
ASTRAZENECA PHARMA
 
P/E (TTM) x 48.4 73.6 65.7% View Chart
P/BV x 2.5 20.7 12.0% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 LUPIN   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    LUPIN
Mar-19
ASTRAZENECA PHARMA
Mar-18
LUPIN/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs9861,278 77.2%   
Low Rs720883 81.6%   
Sales per share (Unadj.) Rs369.5228.4 161.8%  
Earnings per share (Unadj.) Rs13.410.4 129.3%  
Cash flow per share (Unadj.) Rs37.416.3 229.9%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs303.798.8 307.5%  
Shares outstanding (eoy) m452.4925.00 1,810.0%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.34.7 48.8%   
Avg P/E ratio x63.6104.2 61.1%  
P/CF ratio (eoy) x22.866.4 34.4%  
Price / Book Value ratio x2.810.9 25.7%  
Dividend payout %00-   
Avg Mkt Cap Rs m386,06427,008 1,429.5%   
No. of employees `00017.71.4 1,304.1%   
Total wages/salary Rs m31,5131,535 2,052.6%   
Avg. sales/employee Rs Th9,453.84,210.9 224.5%   
Avg. wages/employee Rs Th1,782.01,132.2 157.4%   
Avg. net profit/employee Rs Th343.0191.1 179.5%   
INCOME DATA
Net Sales Rs m167,1825,710 2,927.9%  
Other income Rs m3,640123 2,971.6%   
Total revenues Rs m170,8225,833 2,928.8%   
Gross profit Rs m28,822463 6,226.4%  
Depreciation Rs m10,850147 7,361.0%   
Interest Rs m3,0780-   
Profit before tax Rs m18,534438 4,231.5%   
Minority Interest Rs m-890-   
Prior Period Items Rs m380-   
Extraordinary Inc (Exp) Rs m-3,4000-   
Tax Rs m9,017179 5,040.2%   
Profit after tax Rs m6,066259 2,341.0%  
Gross profit margin %17.28.1 212.7%  
Effective tax rate %48.740.8 119.1%   
Net profit margin %3.64.5 80.0%  
BALANCE SHEET DATA
Current assets Rs m138,5363,209 4,316.8%   
Current liabilities Rs m61,2992,070 2,962.0%   
Net working cap to sales %46.220.0 231.5%  
Current ratio x2.31.6 145.7%  
Inventory Days Days8472 115.8%  
Debtors Days Days11235 322.0%  
Net fixed assets Rs m127,516790 16,135.1%   
Share capital Rs m90550 1,810.0%   
"Free" reserves Rs m136,5172,419 5,642.8%   
Net worth Rs m137,4222,469 5,565.2%   
Long term debt Rs m66,4170-   
Total assets Rs m279,4944,605 6,068.8%  
Interest coverage x7.0NM-  
Debt to equity ratio x0.50-  
Sales to assets ratio x0.61.2 48.2%   
Return on assets %3.35.6 58.2%  
Return on equity %4.410.5 42.1%  
Return on capital %8.917.7 50.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m59,414300 19,834.3%   
Fx outflow Rs m22,2822,015 1,105.9%   
Net fx Rs m37,132-1,715 -2,164.7%   
CASH FLOW
From Operations Rs m16,66088 18,953.0%  
From Investments Rs m-32,825-94 35,069.1%  
From Financial Activity Rs m7,441NA-  
Net Cashflow Rs m-8,724-6 153,047.4%  

Share Holding

Indian Promoters % 46.6 0.0 -  
Foreign collaborators % 0.2 75.0 0.3%  
Indian inst/Mut Fund % 11.3 0.3 3,766.7%  
FIIs % 31.9 15.7 203.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 9.1 111.0%  
Shareholders   98,259 12,856 764.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN With:   TTK HEALTHCARE  ALEMBIC LTD  WYETH LTD  ELDER PHARMA  SUVEN LIFESCIENCES  

Compare LUPIN With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

LUPIN Announces Quarterly Results (1QFY20); Net Profit Up 49.3% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, LUPIN has posted a net profit of Rs 3 bn (up 49.3% YoY). Sales on the other hand came in at Rs 44 bn (up 14.6% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN 2018-19 Annual Report Analysis (Annual Result Update)

Jul 18, 2019 | Updated on Jul 18, 2019

Here's an analysis of the annual report of LUPIN for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

LUPIN Announces Quarterly Results (4QFY19); Net Profit Down 1.5% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, LUPIN has posted a net profit of Rs 3 bn (down 1.5% YoY). Sales on the other hand came in at Rs 44 bn (up 77.8% YoY). Read on for a complete analysis of LUPIN's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN SHARE PRICE


Sep 20, 2019 (Close)

TRACK LUPIN

LUPIN - SHASUN PHARMA COMPARISON

COMPARE LUPIN WITH

MARKET STATS